Securian Asset Management Inc. Has $9.64 Million Stock Position in Danaher Co. (NYSE:DHR)

Securian Asset Management Inc. cut its holdings in shares of Danaher Co. (NYSE:DHR) by 11.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 41,668 shares of the conglomerate’s stock after selling 5,489 shares during the period. Securian Asset Management Inc.’s holdings in Danaher were worth $9,639,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Wellington Management Group LLP lifted its stake in shares of Danaher by 18.6% in the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock valued at $6,185,203,000 after purchasing an additional 3,905,449 shares during the period. Northern Trust Corp lifted its stake in Danaher by 1.7% in the third quarter. Northern Trust Corp now owns 8,100,722 shares of the conglomerate’s stock valued at $2,009,789,000 after buying an additional 134,905 shares during the period. Flossbach Von Storch AG boosted its holdings in Danaher by 1.8% during the fourth quarter. Flossbach Von Storch AG now owns 4,601,351 shares of the conglomerate’s stock worth $1,064,477,000 after buying an additional 82,672 shares during the last quarter. Fisher Asset Management LLC grew its position in shares of Danaher by 6.2% during the 4th quarter. Fisher Asset Management LLC now owns 4,227,108 shares of the conglomerate’s stock worth $977,900,000 after buying an additional 248,140 shares during the period. Finally, Invesco Ltd. increased its stake in shares of Danaher by 13.2% in the 3rd quarter. Invesco Ltd. now owns 4,070,455 shares of the conglomerate’s stock valued at $1,009,880,000 after acquiring an additional 473,693 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In other Danaher news, CEO Rainer Blair sold 9,005 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the sale, the chief executive officer now owns 106,990 shares of the company’s stock, valued at approximately $28,352,350. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Matthew Mcgrew sold 46,377 shares of the stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at $7,441,441.35. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Rainer Blair sold 9,005 shares of Danaher stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the sale, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at approximately $28,352,350. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 172,540 shares of company stock worth $43,523,481. Company insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Barclays upped their target price on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 24th. Citigroup lifted their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. KeyCorp increased their price target on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Bank of America lifted their price objective on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a report on Wednesday, April 24th. Finally, TD Cowen raised their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average price target of $267.31.

Danaher Stock Up 0.4 %

DHR traded up $0.96 on Friday, hitting $265.80. 3,187,418 shares of the company were exchanged, compared to its average volume of 2,621,433. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The stock’s fifty day moving average is $248.74 and its 200-day moving average is $236.50. The company has a market cap of $196.87 billion, a PE ratio of 45.05, a PEG ratio of 4.09 and a beta of 0.83. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $265.94.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.36 EPS. Equities research analysts predict that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 annualized dividend and a yield of 0.41%. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.